Clinical Trial Update: Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the IDH1 inhibitor olutasidenib in a single-plus combo therapy for IDH1-mutant acute myeloid leukemia after induction and cons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING